What's hotT!

View all perspectives
What's Hot

TLL-018 (a JAK1/TYK2 agent) vs. Tofacitinib in RA

Dr. Peter Nash reporting on abstract LB0001 from EULAR 2023 in Milan, Italy.

Watch video →

EULAR 2023 Day 4 Recap

Join Drs. Jack Cush, David Liew and Bella Mehta as they recap data presented on Day 4 at EULAR 2023 in Milan, Italy.

Watch video →

Upadacitinib in SLE

Dr. Peter Nash reports on abstract OP0139 EULAR 2023 in Milan, Italy.

Watch video →

Daily Recap: Day Three EULAR 2023

Drs. Antoni Chan, Jack Cush and Yuz Yusof report from EULAR 2023 in Milan, Italy.

Watch video →

Concomitant Methotrexate Therapy in Psoriatic Arthritis

Dr. Eric Ruderman discusses abstract OP0063 presented at EULAR 2023 in Milan, Italy.

Watch video →

Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases

Dr. Peter Nash reporting from EULAR 2023 in Milan, Italy.

Watch video →

JAKpot or JAKnot

Dr. Jack Cush, executive editor of RheumNow, reporting on abstract OP0219 from EULAR 2023 in Milan, Italy.

Watch video →

Should you Assess Rheumatoid Factor Serially?

Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy.

Watch video →

APIPPRA Study in Preclinical RA

Dr. Jack Cush, executive editor, RheumNow, discussing OP0130 from EULAR 2023 in Milan, Italy.

Watch video →

The Importance of Identifying Central Pain in PsA

Dr. Eric Ruderman discusses abstracts OP0068 and OP0299 at EULAR 2023 in Milan, Italy.

Watch video →

Postpartum Depression in RA

Dr. Jonathan Kay discusses abstract POS0206-HPR at EULAR 2023 in Milan, Italy.

Watch video →

Daily Recap: Day One + Two

Watch video →

CV and Cancer Risk with JAK inhibitors

Dr. Jonathan Kay discusses abstract OP0132 presented at EULAR 2023 in Milan, Italy.

Watch video →

SpA and Interstitial Lung Disease

Dr. Eric Ruderman discusses abstract OP0006 presented at EULAR 2023 in Milan, Italy.

Watch video →

EULAR 2023 Overview: Mindblowers and Head Scratchers

Dr. Jack Cush, executive editor, RheumNow reporting from EULAR 2023 in Milan, Italy.

Watch video →

Baricitinib in Lupus Nephritis

Dr. Peter Nash reports on abstract OP0053 presented at EULAR 2023 in Milan, Italy.

Watch video →
      RT @synovialjoints: Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory res

      Dr. Antoni Chan synovialjoints

      2 years 10 months ago
      Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory response, slight reduction in response compared to general population in both antibody and cell mediated responses Winthrop K, Abst#OP0225 #EULAR2023 @RheumNow https://t.co/wxwbOYsn5K
      RT @Yuz6Yusof: #EULAR2023 #POS0222 Post-hoc Analyses of Phase 3 RCT in Rituximab-treated ANCA vasculitis patients only (

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 10 months ago
      #EULAR2023 #POS0222 Post-hoc Analyses of Phase 3 RCT in Rituximab-treated ANCA vasculitis patients only (65% of total) showed more patients met Remission rate & with lower GC Toxicity vs Pred Taper + RTX at 52 weeks, consistent with Trial Main Results @RheumNow https://t.co/BmiujbhQI9
      RT @AurelieRheumo: Let le introduce you to ARTHUR 🤖

      A very skilled robot who scans your hands and wrists in 15 mn ðŸ

      Aurelie Najm AurelieRheumo

      2 years 10 months ago
      Let le introduce you to ARTHUR 🤖 A very skilled robot who scans your hands and wrists in 15 mn 🤚 Amazing to see new #AI developments that will make our lifes’ easier! #EULAR23 @ROPCA3 @JustSoren Stand M6 @RheumNow https://t.co/7PtR2CGqTt
      RT @drdavidliew: So what kind of changes do we see in ACPA+ arthralgia patients, in the 6 months prior to them developin

      David Liew drdavidliew

      2 years 10 months ago
      So what kind of changes do we see in ACPA+ arthralgia patients, in the 6 months prior to them developing inflamm arthritis? - ACPA titre up, RF pos - EMS, pain up - ESR up Good things to keep an eye on in pre-RA Emery group POS1046 #EULAR2023 @RheumNow https://t.co/cSKPb5SbVH
      RT @drdavidliew: ‘Where have all the rheumatoid nodules gone?’
      (Fantastic poster title @MayoClinic)

      Don’t get to

      David Liew drdavidliew

      2 years 10 months ago
      ‘Where have all the rheumatoid nodules gone?’ (Fantastic poster title @MayoClinic) Don’t get to see them much in clinic anymore. Almost surprised when I do Smoking is down Therapies are better RA is changing (a fact worth remembering!) POS1066 #EULAR2023 @RheumNow https://t.co/VxDNusIjOa
      RT @Yuz6Yusof: #EULAR2023 #POS1069 SLR & meta-analysis to inform EULAR Points to Consider which included 15 studies

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 10 months ago
      #EULAR2023 #POS1069 SLR & meta-analysis to inform EULAR Points to Consider which included 15 studies showed that targeted therapies were not associated with increased risk of cancer recurrence in patients with inflammatory arthritis AND a historyof cancer (85% had RA) @RheumNow https://t.co/uK2XHLjpj8
      RT @drdavidliew: ‘Clinically suspect arthralgias: fact or myth’ - a great debate topic #EULAR2023

      First, the argume

      David Liew drdavidliew

      2 years 10 months ago
      ‘Clinically suspect arthralgias: fact or myth’ - a great debate topic #EULAR2023 First, the argument for. And we start with a reminder as to what we really mean by CSA @RheumNow https://t.co/e1CdxKi69m
      RT @AurelieRheumo: “There was a time when a well-rounded physician had a good grounding in the humanities as well, and

      Aurelie Najm AurelieRheumo

      2 years 10 months ago
      “There was a time when a well-rounded physician had a good grounding in the humanities as well, and we lost that as more teaching time focused on understanding medical science and technology.” Brian Goldman @RheumNow https://t.co/tfXHPRJXAo
      RT @Janetbirdope: To treat or not? Clinically suspect arthralgia does affect QoL including function. Both premises of tr

      Janet Pope Janetbirdope

      2 years 10 months ago
      To treat or not? Clinically suspect arthralgia does affect QoL including function. Both premises of treating with a DMARD are valid. OverRx v missing the very early window of opportunity @RheumNow #EULAR2023 @eular_org https://t.co/86CVZ2IjEf
      RT @synovialjoints: Use of antîmalarials in RA reduced the risk of bacterial infection in RA, smaller number of viral a

      Dr. Antoni Chan synovialjoints

      2 years 10 months ago
      Use of antîmalarials in RA reduced the risk of bacterial infection in RA, smaller number of viral and fungal to study impact on systematic infections Bredemeier M, Abst#OP223 #EULAR2023 @RheumNow https://t.co/RXuFi3LdZC
      RT @Janetbirdope: Should we use #immunesuppression EARLY in #scleroderma to prevent #ILD? Answer from a study comparing

      Janet Pope Janetbirdope

      2 years 10 months ago
      Should we use #immunesuppression EARLY in #scleroderma to prevent #ILD? Answer from a study comparing Y vs N immune suppression- there was no difference in FVC decline. Maybe not a long enough study, ? Chanelling bias scleroderma #lung #disease OP0239 @RheumNow #EULAR2023
      RT @Yuz6Yusof: #EULAR2023 #POS1128 Promising new therapy on the block for #lupus nephritis. A single arm Phase 2a study

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 10 months ago
      #EULAR2023 #POS1128 Promising new therapy on the block for #lupus nephritis. A single arm Phase 2a study showed Zetomipozomib, selective immunoproteosome-i + MMF showed about 2/3 pts met =>50% reduction in uPCR at WK24. No safety signal including low IgG or infection @RheumNow https://t.co/0A8cCW5GVV
      RT @AurelieRheumo: 50% reduction of RF levels
      & Complete seroconversion at M3 predicts LDA and Remission at M6 to M

      Aurelie Najm AurelieRheumo

      2 years 10 months ago
      50% reduction of RF levels & Complete seroconversion at M3 predicts LDA and Remission at M6 to M24 period after treatment initiation. RF responders reach LDA/Rem faster. Exciting data but... SDAI remains the stronger predictor of response at M3 @Rheumnow #EULAR23 OP0272 https://t.co/td1MZEzqag
      RT @drdavidliew: We worried that JAKi + MTX might impair Shingrix efficacy, esp given JAKi HZ risk

      Shingrix nested in u

      David Liew drdavidliew

      2 years 10 months ago
      We worried that JAKi + MTX might impair Shingrix efficacy, esp given JAKi HZ risk Shingrix nested in upa RCT: Response (seroconversion rate, titres, cellular response) less than gen pop, but still very good + only 2/95 had RA flares Vaccinate away! OP0225 #EULAR2023 @RheumNow https://t.co/i4ObRSyYh9
      Daily Recap: Day One + Two
      2 years 10 months ago

      Podcasts

      • EULAR 2023 Day 4 Recap
      • RheumNow Eular 2023 Daily Recap Series - Day4
      • RheumNow Eular 2023 Daily Recap Series - Day3

      Catch up on Conference Podcasts

      ×